Get the latest Science News and Discoveries

Randomized controlled trial confirms Impella CP improves survival in heart attack with cardiogenic shock - EurekAlert

<p>A late breaking clinical trial, presented at the American College of Cardiology conference and simultaneously published in the New England Journal of Medicine, confirms routine use of Impella CP in patients who have had a heart attack with STEMI cardiogenic shock reduces 180-day mortality by 12.7%, compared to the control arm (45.8% vs. 58.5%, p=0.04).</p>

None

Get the Android app